Recent News
Updates on Risks Surrounding Proton Pump Inhibitors (PPIs)
Proton pump inhibitors (PPIs) decrease the production of stomach acid that is responsible for the development of ulcers in the stomach, duodenum and esophagus. However, this grouping of drugs is linked to a variety of risks and side effects, and there is a growing list of lawsuits that have been filed in response to these…
Zostavax 2019 Litigation Updates
Zostavax, a vaccine administered to protect against herpes zoster, otherwise known as shingles, is now being contested in approximately 550 cases in multidistrict litigation (MDL). Here, the Baltimore pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss updates in Zostavax litigation for 2019. Zostavax was Intended to Weaken the Shingles Virus When Zostavax…
Updates on Safety Doubts Surrounding Nuplazid
In June of 2016, antipsychotic pharmaceutical drug Nuplazid was approved as a new method of treating psychosis in Parkinson’s patients. Since it’s release over two years ago, concern has arose regarding the drug, with some claiming it was released before more stringent testing could be completed and others concerned that the possible side effects of…
Drug Watch — Lemtrada
The Food and Drug Administration (FDA) has recently added a warning to the prescribing information of Lemtrada, a pharmaceutical drug used to treat serious multiple sclerosis (MS) cases, after it was found to increase patients’ risk of stroke and blood vessel wall tears in the head and neck areas. Here, the pharmaceutical liability attorneys at…
Opioid Liability for Injury and Death
The opioid industry is facing unprecedented backlash from private citizens and government officials as more individuals fall victim to addiction, injury and even death related to opioid use. Here, the product liability attorneys at The Law Offices of Peter G. Angelos discuss who may be held liable for injuries or death related to opioid use….
Jury Awards $27.8 Million in Damages to Patient Injured by Xarelto®
On December 5, 2017, a Philadelphia jury ordered Bayer AG and Johnson & Johnson to pay over $27 million in damages to a patient injured by the companies’ most lucrative medication, Xarelto®. In a verdict that marks the first patient victory in the ongoing Xarelto® litigation, a Philadelphia jury ordered Bayer AG and Johnson &…
FDA: Clinical Trials Show Increased Risk of Amputation with Invokana
Recent safety communications published by the US Food and Drug Administration indicate that type 2 diabetes drug, Invokana (canagliflozin), can cause increased risk for foot and leg amputations. This announcement was made after data from two clinical studies showed that such amputations were necessary in nearly twice as many patients taking Invokana as compared to…
What Patients Need to Know About Actos
The pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss the dangers of Actos—a common Type 2 Diabetes medication. Actos, a common Type 2 Diabetes medication manufactured by Takeda Pharmaceuticals, has remained at the center of thousands of patient injury lawsuits over the past several years. These lawsuits claim that Takeda Pharmaceuticals withheld…
Xarelto®: A Year in Review
In November, 2015, the U.S. District Court for the Eastern District of Louisiana announced that the first of the Xarelto® bellwether trials, stemming from the Xarelto® multidistrict litigation, would begin in February, 2017. Since that announcement, there have been many updates in the ongoing legal battle against Xarelto® manufacturer Bayer AG and distributer Janssen Pharmaceuticals….